<DOC>
	<DOCNO>NCT02023541</DOCNO>
	<brief_summary>Assess progression-free survival overall survival proton beam therapy ( PBT ) patient resectable vs. unresectable esophageal cancer , assess patient-reported outcome PBT esophageal cancer 6 month follow chemoradiation physician-reported toxicity PBT esophageal cancer .</brief_summary>
	<brief_title>Proton Beam Therapy Treat Esophageal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<criteria>Histologically document adenocarcinoma squamous cell carcinoma cervical thoracic esophagus gastroesophageal junction cardia stomach . Staged PET/CT esophagogastroduodenoscopy ( EGD ) OR CT w/contrast EGD stage II III disease . Endoscopic ultrasound ( EUS ) encourage require . Prior endoscopic mucosal resection ( EMR ) diagnosis stage II III esophageal cancer eligible , irrespective margin status . Induction chemotherapy prior concurrent chemoradiation allow . Prior thoracic radiation allowable degree overlap esophageal radiotherapy treatment deem safe treating radiation oncologist . At least 18 year age . ECOG performance status ≤ 2 ( Karnofsky &gt; 60 % ) Normal bone marrow organ function define : WBC &gt; 2,500/mcL Platelets ≥ 75,000/mcl Total bilirubin ≤ 1.5 x IULN AST ( SGOT ) /ALT ( SGPT ) ≤ 3.0 x IULN Creatinine ≤1.5 x IULN OR creatinine clearance ≥ 50 mL/min/1.73 m2 patient creatinine level institutional normal Women childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control , abstinence ) prior study entry duration study participation . Should woman become pregnant suspect pregnant participating study , must inform treat physician immediately . Ability understand willingness sign IRB approve write informed consent document . English speaker . Financial coverage proton therapy . Planned treatment radiation therapy alone without concurrent chemotherapy chemotherapy alone . Previous concomitant cancer within past 3 year curatively treat carcinoma situ cervix , basal cell carcinoma skin , curative treatment transitional cell carcinoma bladder , low risk prostate cancer . Except prostate cancer ( observe low risk ) , cancer list must treat past 3 year without evidence recurrence time registration . Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia control pacer device , myocardial infarction within 3 month registration , psychiatric illness/social situation would limit compliance study requirement Pregnant and/or breastfeed . Patient must negative pregnancy test within 7 day study entry .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>